HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Psychiatry
Sys. Review
Xanomeline/trospium chloride associated with greater odds of clinical response than several second-generation antipsychotics
New schizophrenia treatment shows fewer weight gains than common drugs
This network meta-analysis of 14,680 adults with schizophrenia compared xanomeline/trospium chloride (KarXT) against eight second-generation…
A new drug combination for schizophrenia may offer better weight management and symptom control compared to several common antipsychotic med…
Aug 1, 2026
Psychiatry
Meta-analysis
Second-generation antipsychotics show higher response rates than placebo for augmenting major depressive disorder
Antipsychotics show promise in treating major depressive disorder
This meta-analysis of 13,616 adults with major depressive disorder evaluated pharmacological augmentation with lithium, triiodothyronine (T3…
Adding specific antipsychotic medications to treatment plans may help adults with major depressive disorder achieve better results than a pl…
Jul 31, 2026
Psychiatry
RCT
Cariprazine showed modest weight reduction versus aripiprazole in schizophrenia patients previously treated with olanzapine
Cariprazine shows modest weight benefit over aripiprazole in schizophrenia patients
This trial compared cariprazine to aripiprazole in patients with schizophrenia who had previously used olanzapine.
A trial found cariprazine linked to slightly more weight loss than aripiprazole in people with schizophrenia, though overall differences wer…
May 1, 2026